ESMO Webinar on Gastric Cancer

Optimising sequential therapy in advanced gastric/GEJ cancer: the importance of appropriate treatment selection to improve treatment outcomes

In this webinar, the panel will review and discuss incorporation of immune checkpoint inhibitors in both first-line treatment for advanced disease and in the adjuvant setting, their impact on subsequent treatment, the current status of targeted therapy and the testing of biomarkers and upcoming combination treatment strategies in patients with gastric/GEJ cancer.

This webinar is part of the ESMO Asia Virtual Oncology Week 2021 (#ESMOasiaweek21), taking place on 17-23 November, and presenting the most important innovations in cancer research and care in 2021, highlighting Asian studies with a strong impact on the science and practice of oncology. Participation is free of charge.

Chair

Ian Chau

Speakers

Markus Moehler, Hanneke van Laarhoven, Takako Nakajima

Programme

• Welcome and Introduction, Prof. Ian Chau, Royal Marsden Hospital, Institute of Cancer Research, London & Surrey, UK
• Incorporating checkpoint inhibitors into early line therapy and its impact on subsequent treatment in gastric/GEJ adenocarcinoma, Prof. Dr. Markus Moehler, MD, Head of GI Oncology, Senior Physician Gastroenterology & Endosonography at Mainz University, Mainz, Germany
• Which, when and how to test for biomarkers in targeted therapy in gastric cancers: HER2 and beyond, Prof. Hanneke van Laarhoven, Head of the Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, Netherlands
• Combination strategies: moving IO forward in gastric cancer, Prof. Takako Nakajima, MD, PhD, Department of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan
• Clinical cased based discussion: Q&A,  
• Conclusions and perspectives, Prof. Ian Chau, Royal Marsden Hospital, Institute of Cancer Research, London & Surrey, UK

Learning objectives

• To understand the current paradigm of incorporating checkpoint inhibitors both in the first line advanced disease and post-operative adjuvant settings and its impact on subsequent treatment in gastric/GEJ adenocarcinoma
• To review the current status of HER2 and other targeted therapy and understand when and how to test for these biomarkers in the patient’s treatment pathway
• To appreciate the upcoming strategies of improving on immunotherapy in gastric cancer
• To review the above objectives via a short clinical cased discussion as well as audience Q&A session.